Effect of minodronate on the speed of sound of the calcaneus in postmenopausal women with an increased risk of fractures: A clinical practice-based observational study  by Iwamoto, Jun & Takada, Tetsuya
Available online at www.sciencedirect.comScienceDirect
Journal of the Chinese Medical Association 78 (2015) 591e596
www.jcma-online.comOriginal Article
Effect of minodronate on the speed of sound of the calcaneus in
postmenopausal women with an increased risk of fractures: A clinical
practice-based observational study
Jun Iwamoto a,*, Tetsuya Takada b
a Institute for Integrated Sports Medicine, Keio University School of Medicine, Tokyo, Japan
b Department of Internal Medicine, Hiyoshi Medical Clinic, Kanagawa, Japan
Received November 5, 2014; accepted April 23, 2015AbstractBackground: We previously reported that alendronate and risedronate reduce the urinary levels of cross-linked N-terminal telopeptides of type I
collagen (NTX) by 44.9% and 34.7%, respectively, at 3 months after the start of treatment, and increase the speed of sound (SOS) of the
calcaneus by 0.6% and 0.65%, respectively, at 12 months after the start of treatment in postmenopausal women with osteoporosis. The aim of the
present clinical practice-based observational study was to examine the effect of treatment with minodronate for 12 months on the SOS of the
calcaneus and on bone turnover markers in postmenopausal women with an increased risk of fractures.
Methods: Forty-two postmenopausal women with osteoporosis or osteopenia with a clinical risk factor for fractures who had been treated with
minodronate for > 12 months were enrolled in the study. The SOS and bone turnover markers were monitored during treatment with min-
odronate for 12 months.
Results: Compared to their baseline values, the urinary levels of NTX at 3 months and the serum levels of alkaline phosphatase at 12 months
were significantly decreased at 47.5% and 25.8%, respectively. At 12 months, the SOS increased modestly, but significantly, by 0.47%,
compared to the baseline value.
Conclusion: The present study confirmed that minodronate suppressed bone turnover and modestly increased the SOS of the calcaneus in
postmenopausal women with an increased risk of fractures.
Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Osteoporosis mostly affects postmenopausal women and
substantially increases the risk of bone fracture. Oral
bisphosphonates such as alendronate and risedronate are
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1726-4901/Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Asspostmenopausal osteoporosis. Oral minodronate, a nitrogen-
containing bisphosphonate, was developed in Japan. A ran-
domized, placebo-controlled, double-blind study demonstrated
that 1 mg of minodronate daily for 2 years reduced the risk of
vertebral fractures by 59% in postmenopausal women with
established osteoporosis.1 A recent randomized controlled trial
(RCT) showed that 50 mg of monthly minodronate had a
similar efficacy as 1 mg daily dose of minodronate in terms of
the bone mineral density (BMD) of the lumbar spine and bone
turnover markers with a similar tolerability in patients with
involutional osteoporosis.2 In Japan, monthly minodronate is
the first-line drug for treating postmenopausal osteoporosisociation. All rights reserved.
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monthly dosing regimen, compared to a weekly dosing
regimen.3
Minodronate increases the BMD of the lumbar spine and
total hip in patients with involutional osteoporosis2; therefore,
using dual-energy X-ray absorptiometry (DXA) to measure
the BMD remains the optimal method for monitoring the
response to minodronate treatment. Quantitative ultrasound
(QUS) is a more recently developed noninvasive method to
determine bone density and structure in vivo. Quantitative
ultrasound parameters such as speed of sound (SOS), broad-
band ultrasound attenuation, and stiffness index can predict
the risk of hip, wrist, and total nonvertebral fractures up to 10
years later.4 Quantitative ultrasound may also provide a better
assessment of the structural changes of bone, compared to
DXA.5
The SOS of the calcaneus can be measured using a QUS
device (CM-200; Elk Corp., Osaka, Japan). We recently re-
ported the effects of 12 months of treatment with alendronate
and risedronate on the SOS and on bone turnover markers in
Japanese postmenopausal women with osteoporosis.6,7
Alendronate and risedronate reduced the urinary levels of
cross-linked N-terminal telopeptides of type I collagen (NTX)
and the serum levels of alkaline phosphatase (ALP), and
modestly increased the SOS. To date, however, very few
studies have examined the effects of minodronate on the SOS
in postmenopausal women with osteoporosis. The aim of the
present clinical practice-based observational study was to
examine the effects of 12 months of minodronate treatment on
the SOS and on the levels of bone turnover markers in Japa-
nese postmenopausal women with an increased risk of
fractures.
2. Methods2.1. Ethics approvalThe present study was performed at Hiyoshi Medical Clinic
(Kanagawa, Japan). The protocol was approved by the Ethics
Committee of Hiyoshi Medical Clinic (Kanagawa, Japan).2.2. Study participantsForty-two Japanese postmenopausal women with an
increased risk of fractures who had been treated with a 50-mg
monthly dose of minodronate for > 12 months were recruited
at the outpatient clinic of Hiyoshi Medical Clinic (Kanagawa,
Japan) during a 5-month period between January 7, 2014 and
June 3, 2014. The dose of minodronate used in this study is the
dose used in Japan to treat osteoporosis in postmenopausal
women, and its safety and efficacy have been demonstrated.2
Patients were eligible if they had postmenopausal osteopo-
rosis or osteopenia with a clinical risk factor for fractures. The
clinical risk factors for fractures included current smoking, a
maternal history of hip fractures, and daily alcohol con-
sumption of  2 units.8 According to the Japanese diagnostic
criteria,9,10 osteoporosis is defined as (1) BMD < 70% of theyoung adult mean (YAM) or the “presence” of osteopenia on
X-ray images of the spine and (2) BMD of 70e80% of the
YAM or “possible” osteopenia on X-ray images of the spine
and a history of osteoporotic fractures. Dual-energy X-ray
absorptiometry of the spine is useful for monitoring osteopo-
rosis in Japanese women and QUS is apparently less useful,11
therefore osteoporosis the was diagnosed by using the SOS
(i.e., < 70% of the YAM or 70e80% of the YAM and a history
of osteoporotic fractures) and the X-ray findings of the spine
(i.e., “presence” of osteopenia or “possible” osteopenia along
with a history of osteoporotic fractures). Osteopenia was
defined as a BMD between 70% and 80% of the YAM but
without any history of osteoporotic fractures.9,10 Patients were
excluded if they had a history of reflux esophagitis, gastric or
duodenal ulcer, gastrectomy, renal failure, or bone diseases
such as cancer-induced bone loss because of aromatase in-
hibitors, primary hyperparathyroidism, hyperthyroidism,
Cushing's syndrome, multiple myeloma, Paget's disease of the
bone, rheumatoid arthritis, or osteogenesis imperfecta.
The assessment before the start of minodronate treatment
included a medical history, physical examination, plain radi-
ography of the thoracic and lumbar spine, measurement of the
SOS of the calcaneus, and biochemical tests of the blood (e.g.,
serum calcium, phosphorus, and ALP) and urine (e.g., NTX).
The urinary NTX levels were also measured at 3 months after
the start of treatment. The serum levels of calcium, phos-
phorus, and ALP, and the SOS of the calcaneus were measured
every 6 months after the start of treatment. We evaluated the
outcome of minodronate treatment after 12 months. The
compliance of all patients for 12-month minodronate treat-
ment was > 90%.2.3. Assessment of morphometric vertebral fracturesPlain lateral X-ray films of the thoracic and lumbar spine
were obtained at the start of treatment to detect evidence of
morphometric vertebral fractures. According to the Japanese
criteria, a vertebral fracture is defined in accordance with the
vertebral height on lateral X-ray films.9,10 In brief, the verte-
bral height is measured at the anterior (A), central (C), and
posterior (P) parts of the vertebral body. A vertebral fracture is
defined as (1) a  20% reduction in the vertebral height (A, C,
and P), compared to the height of the adjacent vertebrae; (2) a
C/A or C/P ratio of < 0.8; or (3) an A/P ratio of < 0.75.
Vertebral fractures were assessed at the T4eL4 level.2.4. Assessment of clinical vertebral and nonvertebral
fracturesLow-traumatic osteoporotic clinical fractures were
assessed. Clinical vertebral fractures were determined by the
clinical symptoms and findings on radiographic or magnetic
resonance images of the lumbar and thoracic spine. Non-
vertebral fractures such as major osteoporotic fractures of the
distal radius, proximal humerus, and hip were determined by
clinical symptoms and radiographic images of the wrist,
shoulder, and hip joints, respectively.
Table 1
Baseline anthropometry, SOS, and biochemical markers of the study
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phosphorus, and ALP and urinary NTXparticipants.
Mean ± SD Rangea
Age (y) 71.8 ± 7.3 55e84
Height (m) 1.54 ± 0.05 1.43e1.67
Body weight (kg) 50.9 ± 6.6 36e63
Body mass index (kg/m2) 21.5 ± 2.4 15.6e27.9The serum calcium, phosphorus, and ALP levels were
measured using standard laboratory techniques. The urinary
NTX levels were measured using an enzyme immunoassay
(EIA).SOS (m/s) 1475 ± 15 1441e1498
SOS as % of YAM 68.2 ± 6.8 53e792.6. Measurement of SOS of the calcaneus
Calcium (mg/dL) 9.2 ± 0.3 8.4e10.0
Phosphorus (mg/dL) 3.3 ± 0.5 1.6e4.6
ALP (IU/L) 233 ± 70 116e416
Urinary NTX (nM BCE/mM Cr) 53.5 ± 15.8 24.6e86.7
ALP ¼ alkaline phosphatase; BCE ¼ bone collagen equivalent;
Cr ¼ creatinine; NTX ¼ cross-linked N-terminal telopeptides of type I
collagen; SD ¼ standard deviation; SOS ¼ speed of sound; YAM ¼ youngThe SOS of the left calcaneus was measured using a QUS
device (CM-200; Elk Corp., Osaka, Japan). The reliability and
reproducibility of this QUS device has already been reported,
and the coefficient of variation is 0.15% using the phantom
technique and 0.27% in vivo.12adult mean.
a The normal ranges of serum calcium, phosphorus, and ALP are
8.4e10.2 mg/dL, 2.5e4.5 mg/dL, and 100e340 IU/L, respectively. The
2.7. Statistical analysisstandard range of urinary NTX is 9.3e54.3 nM BCE/mM Cr. The cutoff values
for bone loss and vertebral fracture risk are 35.3 nM BCE/mM Cr and 54.3 nM
BCE/mM Cr, respectively.Data were expressed as the mean ± standard deviation
(SD). The one-way analysis of variance (ANOVA) with
repeated measurements test was used to determine the sig-
nificance of the longitudinal changes in the SOS and
biochemical markers. The ANOVA with Fisher's protected
least significant difference (PLSD) test was used to perform
multiple comparisons of the SOS and biochemical markers
among the time points. All statistical analyses were performed
using StatView-J5.0 software (SAS Institute, Cary, NC, USA)
on a Windows computer. A significance level of p < 0.05 was
used for all the comparisons.
3. Results(m/s)
15103.1. Characteristics of the study participants at the start








N STable 1 shows the anthropometry, SOS, and biochemical
markers of the study participants at the start of treatment. The
mean age of the women was 71.8 years (range, 55e84 years).
The mean SOS was 1475 m/s, which corresponds to 68.2% of
the YAM. The mean serum calcium, phosphorus, and ALP
levels were 9.2 mg/dL, 3.3 mg/dL, and 233 IU/L, respectively,
which were within the normal ranges (8.4e10.2 mg/dL,
2.5e4.5 mg/dL, and 100e340 IU/L, respectively). The mean
urinary NTX level was 53.5 nmol bone collagen equivalent
(BCE)/mmol creatinine (Cr), which was relatively high but
still within the normal range for Japanese women
(9.3e54.3 nmol BCE/mmol Cr).13 Age (mo)
Fig. 1. Change in the speed of sound. Data are expressed as mean ± standard3.2. Changes in the SOS of the calcaneus
deviation. A one-way analysis of variance (ANOVA) with repeated measure-
ments was used to determine the significance of the longitudinal changes in the
SOS. ANOVA with Fisher's protected least significant difference (PLSD) test
was used to perform multiple comparisons of the speed of sound among time
points. One-way ANOVA with repeated measurements showed a significant
longitudinal increase in the SOS at 12 months ( p ¼ 0.0012). ANOVA with
Fisher's PLSD test showed a significant increase in the SOS at 12 months
( p < 0.05). NS ¼ not significant; SOS ¼ speed of sound.Fig. 1 shows the changes in the SOS of the calcaneus. One-
way ANOVA with repeated measurements test showed a sig-
nificant longitudinal increase in the SOS at 12 months
( p ¼ 0.0012). ANOVA with Fisher's PLSD test showed a
significant increase in the SOS at 12 months ( p < 0.05). The
mean percent change in the SOS from the baseline after 12months of treatment was þ0.47% (Table 2), which were
higher than the coefficient of variation in vivo (0.27%).123.3. Changes in biochemical markersFig. 2 shows the changes in the biochemical markers. After
3 months of treatment, the mean urinary NTX levels had
decreased (26.0 ± 8.6 nmol BCE/mmol Cr). The mean serum
ALP levels also decreased during the 12-month treatment
Table 2
Percent changes in SOS and biochemical markers.
3 mo 6 mo 12 mo
SOS 0.40 ± 0.62 0.47 ± 0.95
Calcium 0.5 ± 4.1 0.8 ± 4.0
Phosphorus 3.0 ± 16.9 1.8 ± 19.2
ALP 21.9 ± 14.7 25.8 ± 14.0
Urinary NTX 47.5 ± 21.1
Data are presented as mean ± SD.
ALP ¼ alkaline phosphatase; NTX ¼ cross-linked N-terminal telopeptides of
type I collagen; SD ¼ standard deviation; SOS ¼ speed of sound.
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measurements showed significant longitudinal decreases in the
serum ALP and urinary NTX levels (for both, p < 0.0001).
ANOVA with Fisher's PLSD test showed significant decreases
in the serum ALP and urinary NTX levels (for both,
p < 0.0001). There were no significant changes in the serum
calcium or phosphorus levels. After 3 months of treatment, the
mean percent change in the urinary NTX level from the
baseline was a decrease of 47.5% (Table 2), whereas the

























Fig. 2. Changes in biochemical markers. Data are expressed as mean ± standard de
was used to determine the significance of the longitudinal changes in the biochemic
test was used to perform multiple comparisons of the biochemical markers among
longitudinal decreases in serum ALP and urinary NTX levels (both p < 0.0001). AN
urinary NTX levels (both p < 0.0001). There were no significant changes in serum
BCE ¼ bone collagen equivalent; NS ¼ not significant; NTX ¼ cross-linked N-teof treatment was a decrease of 21.9% and 25.8%, respectively
(Table 2).3.4. Clinical fracturesDuring the 12-month treatment period, only one patient
experienced a rib fracture.3.5. Adverse eventsNo serious adverse events, such as osteonecrosis of the jaw,
femoral diaphysis atypical fractures, or atrial fibrillation
occurred in the present study, although such events have been
reported in other studies.14e16
4. Discussion
The present study confirmed that treatment with minodro-
nate decreased the urinary NTX by 47.5% at 3 months and
serum ALP levels by 25.8% at 12 months and elicited a


























viation. One-way analysis of variance (ANOVA) with repeated measurements
al markers. ANOVAwith Fisher's protected least significant difference (PLSD)
time points. One-way ANOVAwith repeated measurements showed significant
OVAwith Fisher's PLSD test showed significant decreases in serum ALP and
calcium or phosphorus levels. ALP ¼ alkaline phosphatase; Cr ¼ creatinine;
rminal telopeptides of type I collagen.
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risk of fractures. The objectives of this study were to deter-
mine (1) whether decreases in bone turnover markers would be
similar to those reported in previous studies and (2) whether
the increase in the SOS of the calcaneus would be significantly
greater than the range of reproducibility. We also compared
the effects of minodronate and those of alendronate and
risedronate on the changes in these parameters.
The urinary NTX levels were measured at 3 months after
the start of treatment because the measurement of urinary
NTX levels at this time helps assess whether the antiresorptive
effects of minodronate are sufficient or clinically significant.2
A previous RCT showed that a 50-mg monthly dose of min-
odronate with calcium and vitamin D supplementation de-
creases urinary NTX by ~55% at 3 months and decreases
serum bone-specific ALP by ~55% at 12 months in Japanese
patients with involutional osteoporosis.2 However, no data
have been presented with regard to serum ALP. The 47.5%
decrease in the urinary NTX levels in the present study was
smaller than the decrease in a previous RCT.2 One reason for
this discrepancy is that calcium and vitamin D supplementa-
tion were not used in the present study, unlike the protocol in a
previous RCT.2 This current clinical practice-based observa-
tional study nevertheless confirmed that treatment with min-
odronate for 12 months suppressed bone turnover in
postmenopausal women with an increased risk of fractures. In
the beginning of medication, by using brochures, we instructed
the patients to consume 800 mg of calcium and 800 IU of
vitamin D every day. Optimal vitamin D repletion is believed
to be necessary to maximize the response to antiresorbers in
BMD changes and to reduce the risk of fracture in post-
menopausal women with osteoporosis.17 Thus, improvements
in the vitamin D status may be necessary for greater responses
of the SOS and bone turnover markers to minodronate.
The mean age of the study participants at the start of
treatment was 71.8 years. The reference values of the SOS of
the calcaneus in healthy Japanese women aged 65e69 years,
70e74 years, and 75e79 years are 1487 m/s, 1481 m/s, and
1475 m/s, respectively.18 Treatment with minodronate
increased the SOS of the calcaneus from 1475 m/s at the start
of treatment to 1481 m/s at 12 months. Therefore, it seems that
minodronate may help to increase the SOS of the calcaneus in
postmenopausal women with an increased risk of fractures. At
12 months, the percent increase in SOS from the baseline was
0.47%. This increase appeared to be modest, although it likely
exceeded the coefficient of variation (CV) of the SOS of the
calcaneus in vivo (0.27%).12
The present study was a single-arm study. However, our
previous studies may act as a reference to show the potential
benefits of minodronate over alendronate or risedronate. We
previously reported the effects of 12 months of treatment with
alendronate (35 mg weekly) and risedronate (17.5 mg weekly)
on the SOS and on bone turnover markers in postmenopausal
women with osteoporosis (mean age, 69.0 years and 71.1
years, respectively).6,7 At 3 months after the start of treatment,
alendronate and risedronate reduced the urinary levels of NTX
by 44.9% and by 34.7%, respectively; at 12 months,alendronate and risedronate reduced the serum levels of ALP
by 22.2% and 21.2%, respectively, and increased the SOS of
the calcaneus by 0.6% and 0.65%, respectively. In the present
study, minodronate (50 mg monthly) decreased the urinary
NTX levels by 47.5% at 3 months and the serum levels of ALP
by 25.8% at 12 months, and increased the SOS of the calca-
neus by 0.47% at 12 months in postmenopausal women with
an increased risk of fractures (mean age, 71.8 years). Thus, the
reductions in the urinary levels of NTX were greater with
minodronate than with alendronate or risedronate. This finding
is consistent with the results of RCTs.19,20 However, the in-
crease in the SOS was not greater with minodronate than with
alendronate or risedronate, which suggests that the reduction
in bone turnover may not reflect the improvement of bone
structure and quality.
The present study had notable limitations. First, the study
had a retrospective design and a relatively small sample size,
and the data were collected by conventional medical practices.
Second, the study had no control group. Third, there are no
data regarding the long-term reproducibility of QUS parameter
measurements. Fourth, the participants did not receive either
elemental calcium or natural vitamin D supplementation.
Natural vitamin D supplementation is not prevalent in Japan.
This circumstance makes it difficult to compare the present
study with other studies because most other studies have
involved patients with osteoporosis who have received calcium
and vitamin D supplements. Thus, prospective studies with a
large number of participants are needed to verify the efficacy
and safety of minodronate in combination with calcium and
vitamin D supplementation in Japanese postmenopausal
women with an increased risk of fractures.
In conclusion, the present study confirmed that minodro-
nate suppresses bone turnover, and produces a modest but
significant increase in the SOS of the calcaneus in Japanese
postmenopausal women with an increased risk of fractures.
The results of this study and our previous studies suggest that
alendronate, risedronate, and minodronate have beneficial ef-
fects on bone turnover markers and on the SOS of the
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